Xu Aiqi, Zhu Lewei, Yao Chengcai, Zhou Wen, Guan Ziyun
Department of Breast Oncology, School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong, China.
Authors contributed equally.
Cancer Drug Resist. 2024 Apr 23;7:13. doi: 10.20517/cdr.2023.141. eCollection 2024.
Triple-negative breast cancer (TNBC) is among the most aggressive subtypes of the disease that does not express estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Circular RNAs (circRNAs) are a type of non-coding RNA with a circular shape formed by non-standard splicing or reverse splicing. Numerous circRNAs exhibit abnormal expression in various malignancies, showing their critical role in the emergence and growth of tumors. Recent studies have shown evidence supporting the idea that certain circRNAs regulate the proliferation and metastasis of TNBC. In addition, circRNAs alter metabolism and the immune microenvironment to promote or inhibit the development of TNBC. Notably, circRNAs may affect the efficacy of clinical drug therapy, serve as therapeutic targets, and be used as molecular biomarkers in the future. Herein, we will first summarize the biogenesis and function of circRNAs. Then, we will explain current research on circRNAs related to TNBC and their potential to serve as therapeutic targets or biomarkers for future drug development, providing a new direction and idea for TNBC therapy.
三阴性乳腺癌(TNBC)是该疾病中最具侵袭性的亚型之一,它不表达雌激素受体、孕激素受体和人表皮生长因子受体2。环状RNA(circRNAs)是一类非编码RNA,通过非标准剪接或反向剪接形成环状结构。众多circRNAs在各种恶性肿瘤中呈现异常表达,表明它们在肿瘤的发生和生长中起着关键作用。最近的研究表明,某些circRNAs可调控TNBC的增殖和转移。此外,circRNAs改变代谢和免疫微环境,以促进或抑制TNBC的发展。值得注意的是,circRNAs可能影响临床药物治疗的疗效,作为治疗靶点,并在未来用作分子生物标志物。在此,我们将首先总结circRNAs的生物发生和功能。然后,我们将阐述目前关于与TNBC相关的circRNAs的研究及其作为未来药物开发的治疗靶点或生物标志物的潜力,为TNBC治疗提供新的方向和思路。